Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined 5.8% over the past month. However, a closer look at its sound financials ...

Abbott Laboratories (NYSE:ABT – Free Report) had its target price cut by Raymond James Financial from $142.00 to $141.00 in a research report report published on Friday morning, Benzinga reports ...

We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we ...

Abbott Laboratories (NYSE:ABT – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued on ...

Abbott Laboratories ABT will release earnings results for the second quarter, before the opening bell on Thursday, July 17. Analysts expect the North Chicago, Illinois-based company to report ...

The Mairs & Power Balanced Fund finished the first half of 2025 up 2.66%. The Fund underperformed both the benchmark ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.2% and a 38.2% success rate. Olson covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc.

What Happened? Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.1% in the afternoon session after the company reported second-quarter earnings that beat analyst ...

Abbott Laboratories’ ABT Diabetes Care business has become one of its most dynamic growth engines, driven primarily by its FreeStyle Libre continuous glucose monitoring (CGM) platform. In a relatively ...

Looking for the latest stock opportunities in August 2025? Click to read these top stock picks to consider adding to your ...